Orasis Pharmaceuticals

Corrective Eye Drops for Presbyopia

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in September 2015, Orasis Pharmaceuticals operates with 51–200 employees. The company has raised a total of $121M across 5 funding rounds from 12 investors. In October 2024, Orasis Pharmaceuticals completed a $78M financing round led by.

Business overview

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on developing treatments for presbyopia, the age-related loss of near vision. Its core product, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, is an FDA-approved prescription eye drop designed as an alternative to reading glasses. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology markets with its drug discovery and development efforts.

Strategic signal

In October 2024, Orasis Pharmaceuticals secured a $78 million financing round, led by. This significant capital infusion signals strong investor confidence in the company's market readiness and the commercial potential of its novel eye drop, positioning Orasis for a major entry into the ophthalmic market.

Log in to access full profile

Company Intelligence Q&A

What was the most recent funding event for Orasis Pharmaceuticals?
In October 2024, Orasis Pharmaceuticals completed a $78 million financing round. This funding was led by Arboretum Ventures and Visionary Ventures, and is intended to support the commercial launch of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%.
When did Orasis Pharmaceuticals receive FDA approval for QLOSI™?
Orasis Pharmaceuticals announced FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in October 2023.
Did Orasis Pharmaceuticals submit a New Drug Application for its presbyopia treatment?
Yes, Orasis Pharmaceuticals submitted a New Drug Application for its investigational novel eye drop candidate, CSF-1, for the treatment of presbyopia in January 2023. The FDA accepted this application in February 2023.
Has Orasis Pharmaceuticals entered into any recent licensing agreements?
In October 2024, Orasis Pharmaceuticals announced a licensing agreement with Optus Pharmaceuticals for the commercialization of QLOSI eye drops in Korea.
When did Orasis Pharmaceuticals initiate its Phase 2b clinical study for CSF-1?
Orasis Pharmaceuticals announced the initiation of its Phase 2b clinical study of CSF-1 for the treatment of presbyopia in March 2019.
Log in to access full profile